Table 1.

Clinical studies with novel agents in patients with relapsed/refractory HL after autologous stem cell transplantation.

Studies	Treatment	n	Response	Median duration of response	Progression-free survival
Younes et al.37	Brentuximab, Phase II	102	ORR = 75% CR = 34%	9.7 months	At 5 years: 22%
Ansell et al.40	Nivolumab, Phase I	23	ORR = 87% CR = 17%	Not reported	At 24 weeks: 86%.
Younes et al.42	Nivolumab, Phase II	80	ORR = 66% CR = 9%	7.8 months	At 6 months: 77%
Armand et al.41	Pembrolizumab, Phase	31	ORR = 65% CR = 16%	70% of patients more than 6 months	At 24 weeks: 69%.
Fehringer et al.43	Lenalidomide, Phase II	38	ORR = 19% CR = 16%	6 months	Median: 4 months
Johnston et al.47	Everolimus, Phase II	19	ORR = 47% CR = 5%	7.2 months	Median: 6.2 months
Younes et al.45	Panobinostat, Phase II	129	ORR = 27% CR = 4%	6.9 months	Median: 6.9 months

CR: complete response; ORR: overall response rate.